Proactive Investors - Run By Investors For Investors

Collagen Solutions teams up with UCL to land arthritis grant

Collagen Solutions has won grant funding for its arthritis research with University College London.
Collagen Solutions teams up with UCL to land arthritis grant
Arthritis is the focus of Collagen's latest collaboration.

Collagen Solutions (LON:COS) is part a consortium that has been awarded a grant by Arthritis Research UK.

The funding will cover the development of a man-made osteochondral scaffold for large defect repairs.

Osteochondral injuries are repetitive trauma that occur within a joint such as the knee or elbow.

It is partnering with University College London and Oxford MEStar, a firm specialising in translational and regenerative medicine.

“Our relationship with UCL has already led to the licensing of novel collagen material from the laboratories of professor Brown,” said Collagen Solutions chief executive Stewart White.

“This new grant widens our collaboration with the university and will lead to the development of another collagen based, high value added product which fits in with our strategy of releasing the embedded functionality of our medical grade collagen through the development and commercialisation of high value added novel products."

The size and terms of the grant weren’t revealed.

Collagen Solutions develops and manufactures medical grade collagen components for use in regenerative medicine and medical devices diagnostics.

View full COS profile View Profile

Collagen Solutions PLC Timeline

Related Articles

January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use